• +1-646-491-9876
    • +91-20-67278686

    Search

    Endometrial Cancer-Pipeline Review H1 2017

    Endometrial Cancer-Pipeline Review H1 2017

    • Report Code ID: RW0001834374
    • Category Pharmaceuticals
    • No. of Pages 533
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Endometrial Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

    Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb) . Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 37, 35, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

    Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 6
    Endometrial Cancer - Overview 7
    Endometrial Cancer - Therapeutics Development 8
    Endometrial Cancer - Therapeutics Assessment 21
    Endometrial Cancer - Companies Involved in Therapeutics Development 35
    Endometrial Cancer - Drug Profiles 63
    Endometrial Cancer - Dormant Projects 506
    Endometrial Cancer - Discontinued Products 508
    Endometrial Cancer - Product Development Milestones 509
    Appendix 523

    List of Tables

    Number of Products under Development for Endometrial Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Endometrial Cancer - Pipeline by AbbVie Inc, H1 2017
    Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
    Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
    Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
    Endometrial Cancer - Pipeline by ArQule Inc, H1 2017
    Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
    Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2017
    Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Bayer AG, H1 2017
    Endometrial Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
    Endometrial Cancer - Pipeline by BioNTech AG, H1 2017
    Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Cellceutix Corp, H1 2017
    Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
    Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
    Endometrial Cancer - Pipeline by Eisai Co Ltd, H1 2017
    Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2017
    Endometrial Cancer - Pipeline by Endocyte Inc, H1 2017
    Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Exelixis Inc, H1 2017
    Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Endometrial Cancer - Pipeline by Galena Biopharma Inc, H1 2017
    Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
    Endometrial Cancer - Pipeline by Genmab A/S, H1 2017
    Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
    Endometrial Cancer - Pipeline by Glycotope GmbH, H1 2017
    Endometrial Cancer - Pipeline by Gradalis Inc, H1 2017
    Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2017
    Endometrial Cancer - Pipeline by Immunocore Ltd, H1 2017
    Endometrial Cancer - Pipeline by ImmunoGen Inc, H1 2017
    Endometrial Cancer - Pipeline by Immunomedics Inc, H1 2017
    Endometrial Cancer - Pipeline by Incyte Corp, H1 2017
    Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Endometrial Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
    Endometrial Cancer - Pipeline by MedImmune LLC, H1 2017
    Endometrial Cancer - Pipeline by Merck & Co Inc, H1 2017
    Endometrial Cancer - Pipeline by Merck KGaA, H1 2017
    Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Merus NV, H1 2017
    Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Novartis AG, H1 2017
    Endometrial Cancer - Pipeline by Pfizer Inc, H1 2017
    Endometrial Cancer - Pipeline by Pharma Mar SA, H1 2017
    Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
    Endometrial Cancer - Pipeline by Sanofi, H1 2017
    Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd, H1 2017
    Endometrial Cancer - Pipeline by Sigma-Tau SpA, H1 2017
    Endometrial Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
    Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2017
    Endometrial Cancer - Pipeline by Tesaro Inc, H1 2017
    Endometrial Cancer - Dormant Projects, H1 2017
    Endometrial Cancer - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Endometrial Cancer - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Endometrial Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AbbVie Inc
    Ability Pharmaceuticals SL
    Advenchen Laboratories LLC
    Aeterna Zentaris Inc
    ArQule Inc
    Arrien Pharmaceuticals LLC
    AstraZeneca Plc
    AVEO Pharmaceuticals Inc
    Bayer AG
    BeiGene (Beijing) Co Ltd
    BioNTech AG
    Biscayne Pharmaceuticals Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    CBT Pharmaceuticals Inc
    Cellceutix Corp
    Critical Outcome Technologies Inc
    CytomX Therapeutics Inc
    Eisai Co Ltd
    Eli Lilly and Company
    Endocyte Inc
    Esperance Pharmaceuticals Inc
    Exelixis Inc
    F. Hoffmann-La Roche Ltd
    Galena Biopharma Inc
    GamaMabs Pharma SA
    Genmab A/S
    GlaxoSmithKline Plc
    Glycotope GmbH
    Gradalis Inc
    Horizon Pharma Plc
    Immunocore Ltd
    ImmunoGen Inc
    Immunomedics Inc
    Incyte Corp
    Karyopharm Therapeutics Inc
    Lion Biotechnologies Inc
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    Merrimack Pharmaceuticals Inc
    Merus NV
    Millennium Pharmaceuticals Inc
    Novartis AG
    Pfizer Inc
    Pharma Mar SA
    Pivot Pharmaceuticals Inc
    Puma Biotechnology Inc
    Sanofi
    Shenogen Pharma Group Ltd
    Sigma-Tau SpA
    Syndax Pharmaceuticals Inc
    Synthon Holdings BV
    Tesaro Inc

    Request for Sample

    Report Url https://www.reportsweb.com//endometrial-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//endometrial-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//endometrial-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments